Marculescu, Cristina published the artcileProbing the limits of Q-tag bioconjugation of antibodies, Application of Dbco-maleimide, the publication is Chemical Communications (Cambridge, United Kingdom) (2019), 55(76), 11342-11345, database is CAplus and MEDLINE.
Site-selective labeling of antibodies (Abs) can circumvent problems from heterogeneity of conventional conjugation. Here, the authors evaluate the industrially-applied chemoenzymic ‘Q-tag’ strategy based on transglutaminase-mediated (TGase) amide-bond formation in the generation of 89Zr-radiolabeled antibody conjugates. Despite previously suggested high regioselectivity of TGases, in the anti-Her2 Ab Herceptin more precise native MS indicates only 70-80% functionalization at the target site (Q298H), in competition with modification at other sites, such as Q3H critically close to the CDR1 region.
Chemical Communications (Cambridge, United Kingdom) published new progress about 1395786-30-7. 1395786-30-7 belongs to catalysis-chemistry, auxiliary class Inhibitor, name is Dbco-maleimide, and the molecular formula is C25H21N3O4, Application of Dbco-maleimide.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia